Results 121 to 130 of about 17,302 (216)
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka +6 more
wiley +1 more source
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner +12 more
wiley +1 more source
TP53 mutations and Azacitidine treatment: To be or not to be related?
TP53 mutations and Azacitidine ...
CUNEO, Antonio, RIGOLIN, Gian Matteo
core
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Azacitidine, a DNA methylation inhibitor, is employed for the treatment of acute myeloid leukemia (AML). However, drug resistance remains a major challenge for effective azacitidine chemotherapy, though several studies have attempted to uncover the ...
Heewon Park, Satoru Miyano
core +1 more source
A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia. [PDF]
Amaya ML +16 more
europepmc +1 more source
Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP. [PDF]
Luo Q +14 more
europepmc +1 more source
Treatment of Acute Myeloid Leukemia in the Elderly. [PDF]
Vadnagara H +5 more
europepmc +1 more source
Efficacy and safety of risk-stratified chemotherapy with azacitidine for children with myeloid leukaemia with Down syndrome: protocol for a multicentre phase II trial (JCCG AML-D24). [PDF]
Nakashima K +23 more
europepmc +1 more source
International audienceVenetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do ...
Laribi, Kamel +27 more
core +1 more source

